We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 18, 2021

Gemcitabine + Cisplatin vs Fluorouracil + Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
J. Clin. Oncol 2021 Aug 11;[EPub Ahead of Print], S Hong, Y Zhang, G Yu, P Peng, J Peng, J Jia, X Wu, Y Huang, Y Yang, Q Lin, X Xi, M Xu, D Chen, X Lu, R Wang, X Cao, X Chen, Z Lin, J Xiong, Q Lin, C Xie, Z Li, J Pan, J Li, S Wu, Y Lian, Q Yang, C Zhao, W Fang, L Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading